彭布罗利珠单抗
肿瘤科
三阴性乳腺癌
医学
乳腺癌
内科学
阶段（地层学）
癌症
生物
免疫疗法
古生物学
作者
Peter Schmid,Javier Cortes,Rebecca Dent,Heather L. McArthur,Lajos Pusztai,Sherko Kümmel,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck,Masato Takahashi,Seock‐Ah Im,Michael Untch,Peter A. Fasching,Marie‐Ange Mouret‐Reynier,Theodoros Foukakis,Marta Ferreira,Fátima Cardoso,Xuan Zhou,Vassiliki Karantza,Konstantinos Tryfonidis,Gursel Aktan,Joyce O’Shaughnessy
标识
DOI：10.1056/nejmoa2409932
摘要
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-containing chemotherapy. Here we report the final results for overall survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI
JY
寻道图强
lin
Cloud
CipherSage
穆紫
美好乐松
凤凰
星辰大海
温暖的盼山
hzc
黑白
脑洞疼
Simon
结实的寄柔
可爱的函函
科目三
Owen
只谈风月
霉小欧
皖公网安备34019202002308
